Diabetes and the brain: issues and unmet needs
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus (DM) is associated with an increased risk of mild cognitive impairment, dementia and stroke. The association between DM and dementia appears to be stronger for vascular cognitive impairment than for Alzheimer's disease, suggesting cerebrovascular disease may be an important factor in cognitive impairment in DM. Although the exact mechanisms by which DM affects the brain remain unclear, changes to brain vasculature, disturbances of cerebral insulin signaling, insulin resistance, glucose toxicity, oxidative stress, accumulation of advanced glycation end products, hypoglycemic episodes, and alterations in amyloid metabolism may all be involved. Cognitive impairment and dementia associated with DM may also be mediated via vascular risk factors, in particular brain ischemia, the occurrence of which can have an additive or synergistic effect with concomitant neurodegenerative processes. To date, no drug has been approved for the treatment of vascular dementia and there are no specific pharmacological treatments for preventing or reducing cognitive decline in patients with DM. Most focus has been on tighter management of vascular risk factors, although evidence of reduced cognitive decline through reducing blood pressure, lipid-lowering or tighter glycemic control is inconclusive. Tailored, multimodal therapies may be required to reduce the risk of cognitive dysfunction and decline in patients with DM. The use of pleiotropic drugs with multimodal mechanisms of action (e.g., cerebrolysin, Actovegin) may have a role in the treatment of cognitive dysfunction and their use may warrant further investigation in diabetic populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119 · cited 1×
“target of 180 mg/dL or less resulting in lower mortality than a target of 81–108 mg/dL [30].”
BackgroundGorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Capes, S. E., Hunt, D., Malmberg, K., Pathak, P., & Gerstein, H. C. (2001) · Stroke · doi:10.1161/hs1001.096194 · Cited by 1,824 · cited 1×
“0 in those with known DM when compared to patients with normoglycemia [24].”
BackgroundHypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128 · cited 1×
“Moreover, a history of severe hypoglycemic episodes has also been associated with increased dementia, suggesting any benefits of tighter control may need to be balanced against a higher hypoglycemia risk [47].”
BackgroundGlucose Levels and Risk of Dementia
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., Haneuse, S., Craft, S., Montine, T. J., Kahn, S. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215740 · Cited by 929
Cardiovascular risk factors and cognitive decline in middle-aged adults
Knopman, D., Boland, L. L., Mosley, T., Howard, G., Liao, D., Szklo, M., McGovern, P., & Folsom, A. R. (2001) · Neurology · doi:10.1212/wnl.56.1.42 · Cited by 883 · cited 1×
“Longitudinal studies have also reported accelerated cognitive decline in patients with DM [8, 9].”
BackgroundPeters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Incidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study
Vermeer, S. E., den Heijer, T., Koudstaal, P. J., Oudkerk, M., Hofman, A., & Breteler, M. M. B. (2003) · Stroke · doi:10.1161/01.str.0000052631.98405.15 · Cited by 680
Long-term effect of diabetes and its treatment on cognitive function
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa066397 · Cited by 646
Launer, L. J., Miller, M. E., Williamson, J. D., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M., Horowitz, K. R., Ding, J., Marcovina, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70188-0 · Cited by 574 · cited 1×
“3 Outcomes in the ACCORD-MIND study [46].”
Impact of Metabolic Syndrome on Cognition and Brain: A Selected Review of the Literature
Yates, K. F., Sweat, V., Yau, P. L., Turchiano, M. M., & Convit, A. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.252759 · Cited by 444
Chen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y.-D., Ma, T., Thompson, R. C., Zhao, Y., Smith, L., Gasparini, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807991106 · Cited by 390
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386 · cited 1×
“AD treatments, such as the cholinesterase inhibitors donepezil and galantamine, have shown some cognitive benefits in clinical trials, but effects on global and functional efficacy were less consistent [54, 55].”
BackgroundGouw, A. A., van der Flier, W. M., Fazekas, F., van Straaten, E. C. W., Pantoni, L., Poggesi, A., Inzitari, D., Erkinjuntti, T., Wahlund, L. O., Waldemar, G., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.498535 · Cited by 384
Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice
Li, J., Deng, J., Sheng, W., & Zuo, Z. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.002 · Cited by 260
Mixed Dementia—the Most Common Cause of Dementia
KORCZYN, A. D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04807.x · Cited by 219
Self-citationAn update on type 2 diabetes, vascular dementia and Alzheimer’s disease.
Exalto, L. G., Whitmer, R. A., Kappele, L. J., & Biessels, G. J. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.014 · Cited by 194 · cited 2×
“It has also been suggested that mean cognitive performance was relatively stable over time in both groups, leaving little room for a treatment effect [6].”
BackgroundGalantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
Self-citation
Cited by
Anxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Cocoa, Glucose Tolerance, and Insulin Signaling: Cardiometabolic Protection
Grassi, D., Desideri, G., Mai, F., Martella, L., De Feo, M., Soddu, D., Fellini, E., Veneri, M., Stamerra, C. A., & Ferri, C. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b00913 · Cited by 40
Metadata
- Authors
- Bornstein, N. M., Brainin, M., Guekht, A., Skoog, I., & Korczyn, A. D.
- Venue
- Neurological Sciences
- Published
- 2014-04-29
- Volume
- 35
- Issue
- 7
- Pages
- 995-1001
- ISSN
- 1590-1874 (ISSN-L)
- 1590-3478
- OpenAlex
- W2070553763
- Cited by
- 48
- References
- 22
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.